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ABSTRACT 
Light transmission aggregometry (LTA) and lumi-aggregometry are the gold standard platelet 
assays both clinically and for basic research.  The availability of different strains of genetically 
modified mice, and mouse models of human disease means that often laboratories need to 
use mouse platelets in these assays.  Overall, performing aggregometry and lumi-
aggregometry with mouse platelets is similar to with human platelets, although methods need 
be adapted to accommodate their small size, reduced blood volume and different protein 
levels. This review aims to highlight these key considerations when planning aggregometry 
experiments with mouse platelets.  These include the method of taking blood, including the 
use of anticoagulants, as well as the method of platelet preparation, and how to maximise 
yields.  This review also covers how to maximise the number of aggregations that can be 
performed, both by understanding the minimum requirements of your aggregometer, or by 
considering new approaches.  These include employing high throughput plate-based 
aggregometry (Optimul), or the use of TPO-mimetics to stimulate platelet production in mice 
to boost their platelet counts.  Finally, phenotypic differences between mouse and human 
platelets, such as protein expression or sensitivity to agonists is discussed as an important 
consideration when planning experiments. 
 
INTRODUCTION 
Light transmission aggregometry (LTA) and lumi-aggregometry have remained the gold 
standard platelet function tests for both clinical diagnostics and in basic research.  LTA is a 
relatively simple assay that measures light transmittance of a stirred platelet suspension which 
becomes less turbid as the platelets aggregate.  Lumi-aggregometry utilises the same basic 
setup but with the additional capacity to measure ATP secretion from platelet dense granules 
by the means of luminescence emitted by a luciferin/luciferase reagent added prior to platelet 
stimulation (Figure 1).  These tests have also been widely utilised to characterise the function 
of mouse platelets from genetically modified mice and for this reason have played as much of 
a role in our understanding of platelet biology as LTA performed using human platelets. 
 
Several additional challenges face a researcher that wishes to perform experiments on mouse 
platelets rather than platelets from a human donor.  Whereas obtaining mouse platelets 
requires investment both financially and in the time required to maintain mouse colonies, 
human blood is relatively easy to obtain once appropriate ethical approval and informed 
consent has been obtained.  In a clinical setting, blood samples are taken from patients in a 
hospital/clinic, and may then be used for research in a laboratory. In research labs, healthy 
volunteers may donate blood samples for experiments.  Venepuncture is non-invasive and 
allows volumes of blood ranging from 5-100 mL to be readily taken without any ill effects on 
the donor.  This provides sufficient amounts for a large number of individual aggregations to 
be performed.  In contrast, only very small volumes of blood (approximately 1-1.2 mL) may be 
obtained from a mouse. 
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The additional challenges of working with murine platelets extend to the more complex 
considerations during their preparation relative to human platelets. Human platelet preparation 
for either platelet-rich plasma (PRP) or washed platelets (WP) is simple and straightforward; 
a slow speed centrifugation step to isolate PRP, followed by higher speed spins to pellet and 
wash the platelets [1].  Length, speed and numbers of centrifugation, as well as the addition 
of inhibitors vary by specific purpose and/or the standard protocol in a particular laboratory. 
Although similar in some regards to the methods utilised to prepare human platelets, due to 
the smaller volumes of mouse blood samples additional measures must be taken to maximise 
the volume of PRP or WP obtained from them, both for practical and ethical reasons.  
 
To take advantage of the insights into platelet biology offered by genetically modified mice or 
mouse models of human disease, methods must be adapted to take into account their small 
size, reduced blood volume, and different expression levels of proteins. These considerations 
are the focus of this article, which aims to highlight key considerations when planning 
aggregometry experiments with mouse platelets, rather than providing a detailed method.  For 
detailed methods, see an excellent methods chapter from Cazenave et al [2]. 
 
OBTAINING BLOOD FROM MICE 
Both terminal and non-terminal methods for taking blood from mice can be used. However, 
taking blood via non-terminal methods, such as via tail vein or saphenous vein, only volumes 
less than 200 μL are permissible within a 24 hour period, assuming the total blood volume for 
an adult mouse of average size (25 g) is approximately 1.5 mL.  This is based on NC3Rs 
guidance in the United Kingdom although the value is similar at several universities in the 
United States.  Mice have higher platelet counts than humans, with counts of approximately 
1x106/μL often cited, although values ranging from 4.5x105–1.5x106/μL have been published 
[3-5].  The reason for this range of published platelet counts may be due to differences 
between the strain of mice used, but also due to differences in counting method.  Most 
sources, including numerous phenotypic studies on the Mouse Phenome Database 
(https://phenome.jax.org) agree that the two most commonly used mouse strains, C57Bl/6 and 
Balb/c, both have platelet counts of approximately 1x106/μL [3-7].  Despite having 2–6 fold 
more platelets per μL than humans, 200 μL is unlikely to provide enough platelets for even a 
single LTA experiment.  Furthermore, these methods of blood taking are highly variable with 
regard to the volume of blood extracted, making accurate matching of anticoagulant volume 
difficult.  Therefore, for LTA experiments, terminal bleeding is the only viable option, excepting 
retro-orbital bleeding (see below).   
 
Bleeding via cardiac puncture or via the inferior vena cava (in the abdominal cavity) are two 
commonly used methods of performing a terminal bleed.  These can be performed following 
anaesthesia achieved using either inhalation anaesthetics e.g. isoflurane/O2 (5%), or injected 
anaesthetics e.g. a mixture of ketamine (0.2%) and xylazine (1%).  Alternatively, blood can be 
taken from a CO2 narcosed mouse, ensuring the blood is drawn immediately following 
narcosis, as the stasis in blood flow may cause some pre-activation of the platelets.  Local 
rules will most likely guide the selection of anaesthetic, but it is crucial that blood is taken prior 
to any serious trauma, such as cervical dislocation as this will cause internal bleeding and 
substantial platelet activation. 
 
Following induction of anaesthesia/narcosis, surgery is performed to open the chest or 
abdomen to access to the heart or inferior vena cava respectively.  A small gauge needle 
(25G) attached to a 1 mL syringe should be used to draw the blood.  The syringe should 
contain anticoagulant, most commonly 100 μL of acid-citrate-dextrose (ACD), although 
sodium citrate may be preferable if you want to prepare PRP; the reduced pH from using ACD 
reduces platelet function [2, 8, 9].  Another alternative anticoagulant in common use is low-
molecular weight heparin, which has the advantage of maintaining plasma calcium levels.  
Large volumes (1-1.2 mL or more if the mouse is large) are obtainable by these methods, 
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although patience is required, as the last 20% can be slow once the initial blood pressure is 
lost.  The use of a syringe with these methods allows for accurate recording of volumes and 
anticoagulant ratios.  Immediately following blood taking, the blood is transferred to a tube, 
containing 200 μL of Modified Tyrode’s buffer or further anticoagulant, depending on the 
requirements of the experiment. 
 
Cardiac puncture may also be performed without surgery (but under anaesthesia), by inserting 
the needle through the skin and without any exteriorisation of the heart.  This makes the 
process quicker, but introduces the risk of incorrectly locating the needle, reducing the yield 
or possibly resulting in a failed bleed.  With practice this method can yield similar volumes of 
blood as the surgical methods.   
 
Another non-surgical method is retro-orbital bleeding.  For this method, a glass capillary tube 
is coated with the anticoagulant of choice and broken in half, shortening the length and 
providing a sharp edge at one end.  Following anaesthesia, the sharp end of the capillary is 
inserted behind the eye, into the venous sinus.  The blood is withdrawn by capillary action and 
allowed to drip into a tube containing anticoagulant.  This method allows for rapid blood taking 
of large volumes (1-1.2 mL), although there is likely to be a small amount of contaminating 
tissue fluid.  Also, without the use of a syringe, the true volume taken can only be estimated 
at the time, therefore allowing inaccuracies with anticoagulation.  In the UK, this method can 
only be performed as a terminal procedure, due to the substantial trauma caused to the 
mouse.  However in some countries it is permissible for the mouse to recover, and multiple 
bleeds (~500 μL) performed.  Under these circumstances it would be possible to perform a 
small LTA experiment from a mouse, allow it to recover, and then re-test it at a later date.  This 
could be advantageous for some experiments as platelets from a single mouse could be 
analysed pre- and post-treatment with a drug, or it could be used as a strategy to maximise 
platelets from mutant mice which are rare (e.g. low Mendelian frequencies). 
 
PREPARING PRP OR WASHED PLATELETS 
As with preparing human PRP or washed platelets (WP), there are numerous small variations 
in the methods used for mouse platelets, which won’t be detailed here.  However, generally 
speaking the protocol follows the same format as for human platelets, with the major difference 
being that the volumes are much smaller.  As with human platelets, a slow centrifugation step 
separates PRP from the red cell fraction, from which WP can be isolated with additional higher 
speed centrifugations. 
 
The PRP prepared from blood drawn from a single mouse is likely to be sufficient for only 2-3 
aggregation experiments.  However a potential compromise, owing to the greater platelet 
count of mice, is to dilute the PRP to increase volume without compromising the ability of the 
sample to aggregate.  This can be achieved by performing a platelet count on the isolated 
PRP and adjusting to a predetermined count by diluting in Modified Tyrode’s buffer (counts of 
between 2x108/mL to 4x108/mL are frequently used for aggregometry).  This can be 
supplemented with calcium and fibrinogen to replicate conditions of undiluted plasma, 
although this may only be needed for specific experiments.  As mentioned above, it may be 
advisable to use either sodium citrate or low-molecular weight heparin as an anticoagulant 
rather than ACD in this case, as platelet function is compromised if the pH is below 
physiological levels [2, 8, 9].  
 
As washing protocols result in some degree of desensitisation of the platelet purinergic 
receptors; P2Y1 and P2Y12 during centrifugation steps, another major advantage of diluting 
mouse PRP is that the platelets maintain their sensitivity to ADP [10, 11].  However, the 
presence of plasma proteins may not be compatible with some experiments, for example 
where inhibitors or agonists are substantially plasma bound.  Protocols for washing human 
platelets which maintain their ADP-sensitivity exist, although at the time of writing, it does not 
appear that these have been applied to mouse platelets in the literature.  These protocols 
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usually involve pelleting the platelets with slower speed centrifugations, and in some cases 
also include apyrase to hydrolyse any ADP present.  Potentially these protocols could be 
applied to mouse platelets, but as mouse platelets are approximately half the size of human 
platelets (4.3 fL compared to 8.4 fL), they may not pellet well with slower speed centrifugations.  
Gel filtration is another option to avoid ADP-desensitisation, although it often results in a large 
dilution of the platelets [12-14].  Therefore, for LTA experiments with mouse platelets, the 
likelihood is that an additional centrifugation to concentrate the platelets would be required 
following gel filtration, therefore making the process redundant. 
 
Another difficulty with performing LTA with mouse PRP is the corresponding blank, or Platelet 
Poor Plasma (PPP) required by the aggregometer.  After removing the PRP, the remaining 
blood can be centrifuged at high speed to obtain PPP although this is most likely to be an 
insufficient amount for many aggregometers.  Therefore dilution with buffer, or to use buffer 
alone should be considered. 
Finally, treatment of the buffy coat when preparing mouse platelets requires consideration.  
When preparing human platelets, the slower speed centrifugation separates the PRP from the 
erythrocytes, with the buffy coat easily distinguishable at the interface between the fractions 
(Figure 2).  The buffy coat is avoided when aspirating the PRP as it contains leukocytes.  When 
preparing mouse platelets the buffy coat is often poorly defined following the slow speed 
centrifugation (Figure 2).  Coupled with the significantly smaller volume available compared to 
a human preparation, means that it is advisable to carefully aspirate as much of the PRP as 
possible, including the buffy coat.  An additional 200 μL of Modified Tyrode’s buffer can then 
be added to the remaining red cell fraction, followed by mixing and repeating the slow speed 
centrifugation.  This enables more of the platelets to be separated from the red cell fraction 
and be combined with the previously aspirated PRP.  This step can be repeated as required 
to increase platelet yield, although with diminishing returns.  At this point the PRP from a 
number of mice can be pooled to increase the amount of platelets for experimentation. 
 
PERFORMING AGGREGATIONS 
Once the PRP or WP are prepared, performing aggregations is largely identical to doing so 
with human platelets.  Two considerations are maximising the number of aggregations that 
can be performed with the available platelets and the choice of agonists used. 
 
Maximising aggregations – the simplest way to maximise the number of aggregations possible 
with the amount of platelets available, is to use the lowest platelet count possible.  Platelet 
concentrations of 2x108/mL are commonly used, although 1.5x108/mL will also work [15, 16].  
Reducing the platelet concentration lower than this is not advisable, as aggregation becomes 
less reliable as the platelet concentration is lowered.  Minimising the volume used also 
increases the number of possible aggregations, however, the minimum usable volume will 
depend on the aggregometer being used due to the position of the light path used to detect 
changes in light transmittance.  Rubber spacers that attach to the bottom of cuvettes to raise 
the bottom of the cuvette closer to the light path can be used to reduce the minimum volume 
required.  Care should be taken to ensure that the spacers used do not compromise magnetic 
stirring or light transmission.  Furthermore, it is also advisable to confirm that the pipette tips 
used are of sufficient length to dispense agonist directly into the smaller volume of platelet 
suspension.  Gel loading tips are useful for this purpose.  Additionally, some aggregometers 
have adaptors which allow smaller diameter cuvettes to be used, such as the PAP4 (Bio/Data 
Corporation).  
 
Recently, an alternative LTA technique that utilises 96-well microtitre plates rather than glass 
cuvettes has become widely utilised to measure aggregation of human platelets.  Optical 
multichannel (Optimul) aggregometry is a high throughput adaptation of LTA that measures 
aggregation at an endpoint rather in real time and utilises an orbital plate shaker instead of stir 
bars [17-19]. Use of half-area 96-well plates reduces the volume of PRP or WP required to 40 
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μL per aggregation.  The end-point nature of the assay means that all 96 aggregations can be 
performed simultaneously and measured using a plate reader with the capability to read 
absorbance (Figure 1).  Currently this method has not been adapted to enable measurement 
of ATP secretion via luminescence; therefore it is not compatible for studying platelet dense 
granule secretion. 
 
Recently the Optimul method has been utilised to measure aggregation of mouse platelets 
[20].  The authors of this study reported that that, unlike human, mouse platelets do not 
aggregate well to some standard platelet agonists using this method.  Using Optimul, mouse 
platelets do not respond to arachidonic acid, ristocetin, adrenaline or U46619.  Mouse platelets 
do respond to ADP, as well as to collagen, although unlike human platelets, not to 
concentrations below 5 μg/mL.  Mouse platelets also respond to a PAR4 activating peptide in 
this assay.  We have also performed similar experiments and our data agrees, with no 
substantial aggregation seen with arachidonic acid and the most robust aggregation seen with 
a PAR4 peptide (Figure 3).  Therefore, depending on the experiment, Optimul may be a viable 
option for maximising the amount of aggregations possible with mouse platelets.  
 
In the case of mutant mice which are thrombocytopenic, these strategies may still yield too 
few platelets for LTA experiments.  In these instances, an option is to increase the platelet 
count in the mice prior to experimentation.  Thrombocytopenia in humans can be treated 
clinically with either the TPO-analogue romiplostim (trade name Nplate, produced by Amgen), 
or the small molecule TPO receptor agonist eltrombopag (trade names Revolade (EU) and 
Promacta (USA), produced by GlaxoSmithKline).  A study from 2012 used romiplostim to 
rescue the thrombocytopenia in Myh9-/- mice [21].  Mice were dosed with 100 μg/kg 
romiplostim every 3 days, boosting their platelet levels by 2.5-fold [21].  Interestingly, the 
platelet counts of the wild type control mice were boosted by 8-fold over a four week dosing 
regimen, with maximal platelet counts of approximately 6.5x106/μL being reported.  In a  study 
from 2017, the response to romiplostim was compared between adult and neonatal mice [22].  
Mice were given a single dose of romiplostim (10 – 300 μg/kg) and platelet counts were 
measured daily for 14 days.  Platelet counts peaked between 5-7 days, but were boosted to a 
lesser extent, increasing by a maximum of 4.2-fold [22].  A third study, from 2015 used 
romiplostim to recover platelet counts in mice following chemotherapy-induced 
thrombocytopenia [23].  In this case, mice were dosed within 3 days of chemotherapy-induced 
thrombocytopenia, with a range of concentrations of romiplostim (10 – 1000 μg/kg).  The 
researchers found that does of 100 μg/kg and above were able to reduce the level 
thrombocytopenia and increase the platelet recovery time, however they did not measure the 
effect of romiplostim on untreated mice [23].  These studies show the potential of romiplostim 
to boost platelet counts in mice such that the blood from a single mouse could yield similar 
numbers of platelets as 20-30 mL of human blood.  However, it should be noted that the use 
of romiplostim also caused platelets to be larger and less mature [21, 22].  Therefore, 
experiments using romiplostim to boost platelet counts would require important controls to 
confirm that platelets from romiplostim-treated mice are not phenotypically different to those 
from untreated mice. 
 
Agonist selection – The final consideration when designing an aggregation experiment with 
mouse platelets is the choice of agonist.  In general, regarding agonist choice, an experimental 
design for human platelets can also be used for mouse platelets, with two notable exceptions.  
Mouse platelets do not express the thrombin receptor PAR1.  Therefore, the PAR1 activating 
peptide, TRAP6 cannot be used for LTA with mouse platelets.  Alternatively the PAR4 
activating peptide should be used for LTA with either PRP or WP, or thrombin can be used, 
but for WP only as thrombin will cleave the fibrinogen present in plasma forming a clot [24].  
Mouse platelets also do not express the low affinity IgG receptor FcγRIIA, in fact the gene is 
absent from the mouse genome, only being found in primates.  FcγRIIA is activated by the Fc 
portion of IgG antibodies, and also by the specific antibody IV.3.  FcγRIIA signalling occurs 
both following ligand binding and in a cooperative manner with the integrin αIIbβ3 [25-27], and 
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it is the mechanism of platelet activation in Heparin-Induced Thrombocytopenia (HIT) [28].  
The absence of FcγRIIA from mouse makes the use of other activatory antibodies easier with 
mouse platelets, as there is no non-specific binding to FcγRIIA to take into consideration; in 
human platelets, FcγRIIA must be blocked with IV.3 F(ab) fragments when using antibodies 
as agonists to prevent platelet activation through the IgG receptor. 
 
For agonists which activate both mouse and human platelets, there are small differences in 
sensitivity which may need to be taken into consideration depending on the aim of the 
experiment.  For example, it has been shown that mouse platelets are more sensitive to both 
ADP and thrombin than human platelets, although it should be noted that this was found by 
measuring fibrinogen binding rather than by aggregometry [29].  Another example is 
aggregation stimulated by the podoplanin receptor CLEC-2.  Proteomic data suggests that 
mouse platelets express approximately 10-fold more CLEC-2 compared to human platelets, 
resulting in a slight increase in sensitivity to CLEC-2 agonists [30, 31].  However, the most 
obvious manifestation of this difference is seen with the dependence of human platelets on 
secondary mediators; apyrase and indomethacin inhibit CLEC-2 mediated aggregation in 
humans, but not in mouse platelets [32, 33].  Differences in expression of receptors between 
species should therefore be considered when designing experiments. 
 
CONCLUSION 
Overall, performing aggregometry and lumi-aggregometry with mouse platelets is similar to 
with human platelets.  However, important additional considerations must be taken into 
account when planning experiments such as the method of taking blood, use of anticoagulants 
and the method of platelet preparation, to maximise yield.  Understanding the minimum 
volume requirements of an aggregometer will maximise the number of aggregations that can 
be performed, and this can be taken further by employing high throughput plate-based 
aggregometry (Optimul).  Finally, some agonists are not appropriate for mouse platelets, 
whereas others may show subtle differences in sensitivity between species. 
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FIGURES 
FIGURE 1 – Schematic of light transmission lumi-aggregometry and Optimul.  A)  Light 
Transmission Aggregometry (LTA): A sample of PRP is turbid, allowing only a proportion of 
the incident light to be transmitted.  Following agonist induced platelet aggregation the sample 
is less turbid, allowing more light to be transmitted.  If performing lumi-aggregometry, light is 
also emit from the enzyme luciferase, following ATP secretion from platelet dense granules.  
B)  Optical multichannel (Optimul) aggregometry: Multiple wells of a 96-well microtitre plate 
are filled with PRP for simultaneous aggregations.  Following agonist induced platelet 
aggregation the plate is read in a plate reader, and the endpoint light transmission is 
calculated. 
 
FIGURE 2 – Comparison of human and mouse platelet preparations.  Following the first 
slow speed centrifugations, human blood is separated into three clearly defined layers, with 
the buffy coat separating the Platelet-rich plasma (PRP) and the erythrocyte layers.  With 
mouse blood, the buffy coat layer is less clearly defined.  When aspirating human PRP, the 
buffy coat is avoided, but when aspirating mouse PRP the buffy coat should also be removed 
to maximise platelet yield.  
 
FIGURE 3 – Optical multichannel (Optimul) aggregometry with mouse platelets.  96-well 
microtitre plates were coated with gelatine to block surface activation of platelets prior to 
addition of the platelet agonists (AA=arachidonic acid).  40 μL of PRP (or PPP as a control) 
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was added into the wells and the plate was placed on an orbital plate shaker, heated at 37ºC 
and mixed at 1200 rpm, for 5 minutes.  Absorbance was then measured at 650 nm on a 96-
well plate reader. Platelet aggregation was expressed as the maximal percent change in light 
transmittance from PRP wells in response to agonists, using PPP as reference, n=5-7, error 
bars represent the standard error of the mean (s.e.m.). 
 
